dendranib

Dendranib is a first-in-class, hydroxyl dendrimer-based small molecule drug developed by Ashvattha Therapeutics. It acts primarily as a potent tyrosine kinase inhibitor, antagonizing colony stimulating factor 1 receptor (CSF1R), vascular endothelial growth factor receptor (VEGFR), and other tyrosine kinases. Dendranib's design enables selective targeting of activated macrophages and microglia, particularly within regions of inflammation and in diseases characterized by neuroinflammation or pathological angiogenesis. Mechanistically, dendranib polarizes macrophages toward an anti-inflammatory (M2) phenotype, suppresses angiogenesis, and reduces neuroinflammation by inhibiting CSF1R and VEGFR signaling in diseased tissue including the retina and central nervous system. It is formulated as a precision nanomedicine using covalent linkage to a hydroxyl dendrimer, allowing efficient crossing of the blood-retinal and blood-brain barriers, and site-selective cellular uptake. Dendranib is being investigated for subcutaneous administration for ophthalmic conditions and preclinical development in neurodegenerative and neuroinflammatory diseases, with favorable safety, minimal systemic exposure, and promising efficacy in reducing disease burden, inflammation, and angiogenesis[1][2][3][5][6][10][14][19].

Brand names

migaldendranib

Other names

dendranib nanomedicineCSF1R dendranibCSF-1R dendranibCSF 1R dendranib